Home Cart Sign in  
Chemical Structure| 942195-55-3 Chemical Structure| 942195-55-3

Structure of Tegoprazan
CAS No.: 942195-55-3

Chemical Structure| 942195-55-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tegoprazan is a potassium-competitive acid blocker specifically targeting gastric acid secretion. It effectively relieves excess gastric acid and related gastrointestinal symptoms by highly selectively inhibiting the H+/K+-ATPase, holding potential therapeutic value for gastroesophageal reflux disease and gastric ulcers.

Synonyms: CJ-12420; RQ-00000004; LXI-15028

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tegoprazan

CAS No. :942195-55-3
Formula : C20H19F2N3O3
M.W : 387.38
SMILES Code : FC1=C2[C@H](CCOC2=CC(F)=C1)OC3=C4NC(C)=NC4=CC(C(N(C)C)=O)=C3
Synonyms :
CJ-12420; RQ-00000004; LXI-15028
MDL No. :MFCD30533430

Safety of Tegoprazan

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone-marrow-derived macrophages (BMMs) 0.5, 1, 10, 100 µg/mL 24 hours To evaluate the effects of Tegoprazan on cytotoxicity and NO production in BMMs. Results showed that TEGO significantly inhibited NO production at 100 µg/mL concentration, with cell viability exceeding 80%. Int J Mol Sci. 2023 Sep 26;24(19):14589
HT-29 10 µM 3 days To evaluate the mitigating effect of Tegoprazan on indomethacin-induced inhibition of cell proliferation. Results showed that Tegoprazan significantly alleviated the inhibition of cell proliferation induced by indomethacin in HT-29 cells. Sci Rep. 2024 Nov 8;14(1):27173
Caco-2 10-100 µM 3 days To evaluate the mitigating effect of Tegoprazan on indomethacin-induced inhibition of cell proliferation. Results showed that Tegoprazan significantly alleviated the inhibition of cell proliferation induced by indomethacin in Caco-2 cells. Sci Rep. 2024 Nov 8;14(1):27173
HIEC-6 1-100 µM 3 days To evaluate the mitigating effect of Tegoprazan on indomethacin-induced inhibition of cell proliferation. Results showed that Tegoprazan significantly alleviated the inhibition of cell proliferation induced by indomethacin in HIEC-6 cells. Sci Rep. 2024 Nov 8;14(1):27173
Caco-2 1.0 mM and 3.0 mM 48 hours Evaluated the protective effect of Tegoprazan on intestinal epithelial barrier function, showing that Tegoprazan significantly suppressed TNF-a-induced reduction in TEER levels and reduced FITC-dextran flux. Front Immunol. 2022 May 25;13:870817
Het-1A cells 30 µM 6 hours To evaluate the effect of Tegoprazan on HCl-induced inflammatory responses. Tegoprazan significantly inhibited HCl-induced pro-inflammatory cytokines (IL-6, IL-8, IL-1β, and TNF-α) but did not significantly affect pyroptosis rate. Front Immunol. 2024 Dec 16;15:1410904.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice DNBS and DSS-induced colitis models Oral 30 mg/kg Twice daily, throughout the experiment Evaluated the protective effect of Tegoprazan on colitis, showing that Tegoprazan significantly improved symptoms of DNBS and DSS-induced colitis, including weight loss, colon shortening, and inflammatory cell infiltration. Front Immunol. 2022 May 25;13:870817
Healthy male subjects Healthy male subjects Oral 50 mg Once daily for 7 days To evaluate the pharmacokinetics and safety of Tegoprazan when co-administered with atorvastatin. Results showed no significant changes in the systemic exposure of atorvastatin when co-administered with Tegoprazan. Front Pharmacol. 2021 Nov 11;12:754849

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05786807 Helicobacter Pylori-positive W... More >>ith Functional Dyspepsia Less << PHASE4 RECRUITING 2023-12-31 Wonkwang University Hospital, ... More >>Iksan, Jeollabuk, 15865, Korea, Republic of Less <<
NCT05577468 Helicobacter Pylori Infection PHASE3 COMPLETED 2023-09-30 Peking University Third Hospit... More >>al, Beijing, Beijing, 100191, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.58mL

0.52mL

0.26mL

12.91mL

2.58mL

1.29mL

25.81mL

5.16mL

2.58mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories